Kenvue Inc. (NYSE:KVUE) Receives Average Rating of “Hold” from Analysts

Kenvue Inc. (NYSE:KVUE) has earned an average rating of “Hold” from the twelve research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $23.08.

A number of analysts have recently commented on the stock. Barclays cut their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday. UBS Group dropped their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday. Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th.

Hedge Funds Weigh In On Kenvue

Large investors have recently made changes to their positions in the stock. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Riverview Trust Co acquired a new stake in Kenvue during the 3rd quarter worth approximately $30,000. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the 3rd quarter worth approximately $35,000. Finally, Versant Capital Management Inc lifted its holdings in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 0.4 %

KVUE stock opened at $21.11 on Friday. The stock has a market capitalization of $40.46 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. The firm has a 50-day simple moving average of $22.42 and a 200-day simple moving average of $21.69. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.31 earnings per share. Equities analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. Kenvue’s dividend payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.